Executive appointments at Merck & Co, Actelion and Jazz Pharma

US drug giant Merck & Co (NYSE: MRK) has appointed Cuong Viet Do as chief strategy officer, effective October 3. In this position he will be responsible for both developing and executing enterprise-wide strategy and further building connections between the current and future business plans of Merck’s franchises, divisions, and functions. He will report to Kenneth Frazier, Merck’s president and chief executive, and will serve on the company’s executive committee. He succeeds Mervyn Turner, who retired from the company this summer.

Since 2009, Cuong Viet Do served as senior vice president of corporate strategy and business development at TE Connectivity, formerly Tyco Electronics, a global company that designs, manufactures and markets products for customers in a variety of industries. While at TE Connectivity, he led a global team of senior executives responsible for charting the company's overall corporate strategy, including strategies for the company's more than 20 business units and key emerging markets. He also developed the company's strategic approach to mergers and acquisitions.

Ex-GSK chief becomes chairman of Actelion